Free Trial
NASDAQ:GYRE

Gyre Therapeutics Q4 2025 Earnings Results & Report

Gyre Therapeutics logo
$4.74 +0.44 (+10.09%)
As of 01:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Gyre Therapeutics missed analyst earnings expectations but beat on revenue in its Q4 2025 results, released March 12, 2026. The company reported EPS of $0.04 versus the $0.08 consensus estimate, while revenue of $37.20 million topped the $36.30 million estimate by $892.00 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Gyre Therapeutics EPS Results

Actual EPS
$0.04
Consensus EPS
$0.08
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Gyre Therapeutics Revenue Results

Actual Revenue
$37.20 million
Expected Revenue
$36.30 million
Beat/Miss
Beat by +$892.00 thousand
YoY Revenue Growth
N/A

Gyre Therapeutics Q4 2025 Earnings FAQ

Gyre Therapeutics (NASDAQ:GYRE) reported earnings of $0.04 per share for Q4 2025, missing the consensus estimate of $0.08. The report was announced on Thursday, March 12, 2026.

Gyre Therapeutics reported revenue of $37.20 million for Q4 2025, against a consensus estimate of $36.30 million.

Gyre Therapeutics Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE) is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals.

Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

The company adopted the Gyre Therapeutics name in 2023, following its predecessor Catalyst Biosciences’ acquisition of a majority stake in Gyre Pharmaceuticals. This brought together U.S.-based drug development activities and established pharmaceutical operations in China.

View Gyre Therapeutics Profile